Aviceda Announces AVD-104, a Novel Glycomimetic Nanoparticle, Demonstrates Continued Clinical Safety
Positive Data Presented at Recent European Congress; Additional Forthcoming Data to be Presented at US Healthcare Conference.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a privately held, late-stage clinical biotech company focused on developing next-generation immunomodulators by harnessing the power of...
Source: pharmiweb.com